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OBJECTIVES: Melanoma is the ﬁ rst mortality cause by skin cancer. The more 
advanced stages prognosis is remaining poor. The MELODY study had as primary 
objectives to describe the disease characteristics, treatment modalities/outcomes, and 
resources use in patients with unresectable Stage III-Stage IV (UNRSIII-SIV) mela-
noma. METHODS: MELODY was a three-country (France, Italy, UK) longitudinal, 
retrospective, observational survey. In the French cohort, 10 expert dermatology 
departments had to register all melanomas seen between July 2005 and June 2006. 
The UNRSIII-SIV cases, with minimum 2-month follow-up, were extracted for 
detailed description of the disease characteristics, treatments (systemic, local, sup-
portive care), and outcomes and resource use, until May 1, 2008 or death. RESULTS: 
In France, 1224 patients (pts) were registered, in which 278 UNRSIII-SIV cases were 
extracted. At initial diagnosis, 34/1224 pts (2.8%) were UNRSIII-SIV; 253 pts (91%) 
received systemic treatment, while 230 (91%) had a chemotherapy of any line. In 
ﬁ rst-line systemic (n = 249), 198 pts (80%) were treated outside clinical trials, in 
whom 119 (60%) were on dacarbazine (D) and 35 (18%) on fotemustine (F) mono-
therapy; complete/partial response was noted for 21 pts (11%), with 2.9-month 
median response duration, median of progression-free survival (PFS) was 2.8 months 
(2.6; 3.5). In second line, 159 pts (57%) were treated, in whom 139 (87%) outside 
of clinical trials, with 75 (54%) on F, and 16 (12%) on D; median PFS was 2.5 months 
(2.1; 3.9). In case of systemic treatment/supportive care, there was a median of 20 
(11; 30) hospitalization days (13 [6; 22] days for ﬁ rst line systemic) and 3 [1; 6] 
outpatient visits (1.5 [1.0; 5.0] for ﬁ rst-line systemic). CONCLUSIONS: In the French 
cohort of MELODY, chemotherapy treatments gave modest results in terms of com-
plete/partial response and PFS, at a high cost of resource use, highlighting the unmet 
medical need. 
CANCER – Patient-Reported Outcomes Studies
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OBJECTIVES: The incidence of malignant melanoma has been continuously growing; 
however, early identiﬁ cation contributes signiﬁ cantly to its effective treatment. As a 
prerequisite, the individual needs to see a specialist soon after the recognition of the 
ﬁ rst symptoms. Therefore, the aim of our study is to disclose the factors and patient 
attitude behind seeing a specialist in case of skin deformation in order to establish the 
method for effective treatment. METHODS: Retrospective cross-sectional study was 
carried out among patients in four cities (n = 280) who had been diagnosed with 
malignant melanoma within 5 years. Besides sociodemographic data, the questionnaire 
focused on the awareness and knowledge of the patient regarding melanoma, on risk 
factors, the general attitude of seeing doctors, and that of delaying factors in respect 
of melanoma. Single and multiple logistic regression were used in statistical analysis. 
RESULTS: After the recognition of skin deformation, only half of the patients visit a 
doctor within 1 year. The increase of latency (seeing a specialist more than 3 months 
after the incidence of the ﬁ rst symptoms) was four to seven times more frequent among 
those who demonstrate anxiety and distress, feel exposed to doctors, lie in the sun 
without any control, lack awareness of the disease, and have a lower rate of social 
support (P < 0.01). The study also revealed the shortages of primary care (e.g., insuf-
ﬁ cient examination, lack of information supply). Seeing a specialist in most of the 
cases was motivated by external factors. CONCLUSIONS: To estimate the beneﬁ t of 
developing programs focusing on health behavior and awareness building of the 
prevalence and incidence of malignant melanoma instead of facilitating several preven-
tive interventional projects based on the screening of the population.
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OBJECTIVES: To identify the association of sociodemographic, resource use, and 
adverse events variables with adherence to measure the return on investment of a 
patient education service for colorectal cancer patients taking capecitabine. 
METHODS: This was a prospective intervention of government patients in the 
country of Mexico of any age, with colorectal cancer and capecitabine treatment. The 
intervention group had access to a hot line, booklets, nutritional and psychological 
support; control group patients did not. a structured ad-hoc questionnaire applied the 
Morisky–Green Test to determine adherence to therapy via follow-up phone calls. 
Associations between variables and adherence between intervention group and con-
trols were assessed using chi-square test. Emergency rooms (ER) visits were the eco-
nomic indicator to establish cost differences between groups. Power analysis was 
conducted using PS Power and Sample Size Calculations version 3.0, January 2009. 
RESULTS: A total of 220 patients were included in this study (mean age 58.4 [26 to 
89] years), 121 intervention patients (48 responded to ﬁ rst call; 70% adherence) and 
99 control patients (30 responded to ﬁ rst call; 57% adherence). If the true odds ratio 
for adherence in intervention relative to control is 1.86, a power analysis projects 
statistical signiﬁ cance with 290 intervention patients and 181 controls to reject the 
null hypothesis with a probability (power) of 0.8. The reason for nonadherence “Does 
not know administration regime” did show statistical signiﬁ cance (P = 0.019) between 
the intervention (10% n = 2) and control group (47% n = 7). For ER visits related to 
adverse events, the control group rate was 13.33% (n = 4) versus 2.32% (n = 1) in 
the intervention group (P = 0.067). The cost for ER/day is $Mex 1,144.44 (USD 
86.82). CONCLUSIONS: These preliminary results indicate that patients who receive 
intervention services may have improved adherence to medication and therefore fewer 
ER visits and costs. Continued enrollment will be able to determine true 
signiﬁ cance.
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OBJECTIVES: In the ToGA study, patients with HER2+ aGC (n = 584) who received 
trastuzumab + chemotherapy achieved signiﬁ cantly improved overall survival com-
pared to patients receiving chemotherapy alone (HR = 0.74 (95% CI 0.60; 0.91, P = 
0.0046; van Cutsem et al. 2009). Since published utilities in gastric cancer are rare, 
we report results of the EQ-5D analysis from ToGA here, particularly the obtained 
utility for progression-free-survival (PFS). METHODS: The EQ-5D was provided to 
patients at baseline and every 3 weeks until disease progression. The questionnaire 
was completed by the patient prior to any study speciﬁ c assessment or discussion with 
their study care provider. Patients’ EQ-5D responses were scored using UK-tariffs, 
according to the guidelines of the EuroQol group. Only fully completed questionnaires 
were included. Mixed effects random slope models in SAS v8.2 were developed to 
estimate the health state utility. The intercept and day of assessment were incorporated 
as random effects. Covariance structures were assessed for goodness of ﬁ t using Akaike 
Information Criteria. Secondary analyses that included a treatment indicator were 
performed to explore a possible treatment effect. EQ-5D analysis of a patient subgroup 
(with tumors highly expressing the HER2-protein, i.e., IHC3+ or IHC2+ and FISH+, 
metastatic at screening, n = 431), was also conducted. RESULTS: The unstructured 
covariance matrix was found to be the best ﬁ t and resulted into a PFS-utility of 0.73 
(95% CI: 0.71; 0.75). The treatment effect was not found to be signiﬁ cant (P = 
0.1542); i.e., no difference between the two treatment regimens was identiﬁ ed. Results 
were conﬁ rmed for the subgroup. CONCLUSIONS: Although only HER2+ patients 
were included in ToGA, the obtained utility value is in line with other published PFS-
utilities in aGC. Given the large patient numbers, 0.73 can be regarded as a robust 
estimate of a patient-reported outcome. Further studies in aGC should attempt to 
assess the utility in patients following disease progression.
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OBJECTIVES: In the UK, chronic lymphocytic leukemia (CLL) makes up 40% of all 
leukemias in patients over 65 years. The objective of this UK-based study was to obtain 
societal preferences for “progression-free” and “progressive” stages of late-stage CLL, 
and selected treatment-related adverse events. METHODS: A utility study, using the 
time-trade off (TTO) method, was conducted in the UK with 110 members of the 
general public for a baseline disease state (before treatment), three primary disease 
states (progression-free survival [PFS] response, PFS non-response, and disease pro-
gression) and four adverse event (AE) substates (PFS response with thrombocytopenia, 
neutropenia or severe infection, and PFS non-response with severe infection). Disease 
state vignettes were developed using literature and validated by expert CLL clinicians. 
Face-to-face interviews were conducted by trained interviewers. The TTO scores were 
converted into a utility value for each disease state and disutilities were calculated for 
AEs. Visual analogue scale (VAS) scores were also obtained. RESULTS: All partici-
pants were included in the analysis. The mean utility scores from the TTO for the 
primary disease states were: baseline: 0.549; PFS response: 0.671; PFS nonresponse: 
0.394; and progression: 0.294. The mean TTO utility (disutility) scores for the AEs 
were: PFS response with thrombocytopenia, neutropenia, or infection, 0.563 (−0.108), 
0.508 (−0.163), 0.476 (−0.195), respectively; PFS nonresponse with infection, 0.333 
(−0.061). The VAS results were in line with the TTO results. CONCLUSIONS: 
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Overall, the utility was higher for the PFS state than for baseline, but decreased below 
baseline in nonresponse and disease progression states. AEs had an important impact 
on utility within the PFS response state. The severe infection AE appeared to have a 
greater impact on patients responding to treatment compared to nonresponders, which 
may be related to the quality of life which is already low for the latter.
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OBJECTIVES: To estimate utility values associated with CML-CP health states among 
members of the general public in the UK. METHODS: Interviewer-administered time 
trade-off utilities were elicited for four CML-CP health states related to risk of progres-
sion, from a random sample of 241 members of the general public from eight cities 
across the UK, using health-state descriptions validated by clinicians and members of 
the general public. Mean utility values with 95% conﬁ dence intervals (CI) were cal-
culated for each health state. RESULTS: The respondents’ mean age was 45 years and 
51% were female. Seven percent (n = 18) of respondents had a cancer at the time of 
the interview which had been diagnosed for a mean 7.0 ± 6.5 years. The mean utilities 
with 95% CI were: 0.72 (0.69; 0.75) for untreated chronic phase CML, 0.80 (0.79; 
0.82) for hematologic response, 0.89 (0.87; 0.90) for cytogenetic response, and 0.94 
(0.94; 0.95) for molecular response. The utility values for each state are signiﬁ cantly 
different from one another (P < 0.001). The respondents’ preference values for any of 
the states were not signiﬁ cantly affected by their demographics or whether they had 
cancer. Nevertheless, the values elicited from respondents with cancer were lower than 
those elicited from respondents who did not have cancer: 0.65 versus 0.73 for chronic 
phase CML; 0.72 versus 0.81 for hematologic response; 0.83 versus 0.89 for cytoge-
netic response; and 0.89 versus 0.95 for molecular response. CONCLUSIONS: The 
health states with poorer outcome (e.g., hematologic response) were associated with 
a lower preference value than the state with the best outcome (i.e., molecular 
response). The data demonstrate the impact that different treatment responses may 
have on the health-related quality of life of patients with chronic phase CML and can 
be used to estimate the outcomes of interventions in terms of quality-adjusted 
life-years.
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OBJECTIVES: We investigated the effect of adjuvant chemotherapy regimens on 
utility scores assessed by the EQ-5D instrument in a randomized controlled trial for 
breast cancer patients after surgery. METHODS: In the National Surgical Adjuvant 
Study of Breast Cancer-02 (N-SAS BC 02), 1060 patients were randomly assigned 
to the following four chemotherapy groups: 1) four cycles of anthracycline (ADM 
60 mg/m2 or EPR 75 mg/m2 + CPM 600 mg/m2, q3 wks x 4) followed by paclitaxel 
(175 mg/m2, q3 wks x 4) (ACP); 2) four cycles of anthracycline followed by docetaxel 
(75 mg/m2 q3, wks x 4) (ACD); 3) eight cycles of paclitaxel (175 mg/m2, q3 wks x 8) 
(PTX); and 4) eight cycles of docetaxel (75 mg/m2, q3 wks x 8). The ﬁ rst consecutively 
registered 300 women were the subjects of the present utility study. Utility scores were 
assessed using the EQ-5D instrument at baseline, 3rd cycle, 5th cycle, 7th cycle, 7 
months, and 1 year. The obtained data were analyzed using a linear mixed model with 
baseline, time, group, and interaction between time and group as explanatory vari-
ables. RESULTS: Missing data was observed between 1.9 and 6.1% of cases depend-
ing on the time of measurement. The utility score was signiﬁ cantly lower in the DTX 
group than in the ACP and ACD groups. In the DTX group, the mean utility score 
was lowest at 7 months, and it tended to remain low for a long time. In a comparison 
of the anthracycline and taxane groups, the anthracycline group had signiﬁ cantly 
higher utility scores. There were no signiﬁ cant differences depending on the type of 
taxane. The estimated mean utility scores were 0.81, 0.83, 0.79, and 0.76 (ACP, ACD, 
PTX, and DTX group). CONCLUSIONS: The results of this study will be beneﬁ cial 
not only for clinical decision-making but also for appropriate allocation of medical 
resources.
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OBJECTIVES: Survival and quality of life (utility) are often the main measure of 
beneﬁ t used in an economic evaluation. Additionally, some decision-makers will 
consider beneﬁ ts in terms of work productivity. The present study was designed to 
estimate utilities and productivity loss for women with metastatic breast cancer (MBC) 
which is Human Epidermal Growth Factor Receptor 2 positive (HER 2+). METHODS: 
Health-state vignettes describing MBC progressive disease, stable disease, and seven 
grade 3/4 adverse events (diarrhea, fatigue, anemia, leukopenia, anorexia, decreases 
in left ventricular ejection fraction [LVEF], and skin rash) were developed based on 
interviews with women with MBC in the The Netherlands and Sweden and clinicians. 
a general public sample rated the states (100 men and women in NL; 100 women 
aged 50+ in Sweden) using the time trade off method. Women (161 The Netherlands, 
52 Sweden) who were currently or recently treated for MBC were surveyed using the 
Work Productivity and Activity Impairment scale regarding the impact of disease on 
their ability to work. RESULTS: MBC progressive disease and stable disease were 
rated more highly in Sweden (0.61, 0.81) than the The Netherlands (0.50, 0.69). 
Utilities for toxicities ranged from 0.52 to 0.69 (Sweden), and 0.47 to 0.66 (NL). The 
productivity survey identiﬁ ed that women currently receiving treatment reported that 
their overall productivity was reduced by 69% (NL) and 72% (Sweden); while those 
who had recently completed therapy reported reductions of 41% (NL) and 40% 
(Sweden). CONCLUSIONS: This study captured utility and productivity data for the 
The Netherlands and Sweden regarding the impact of HER 2+ MBC. Important dif-
ferences in utilities emerged in the study which could impact cost-effectiveness esti-
mates. The productivity survey demonstrated how the negative impact of breast cancer 
on productivity persists after women have completed their treatment.
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OBJECTIVES: Previous studies in cancer patients have found scores of ≥5 on 11-point 
pain scales to indicate pain that has a signiﬁ cant impact on patients’ lives. This study 
sought to conﬁ rm the adequacy of a ≥5 cutpoint on the BPI-SF “worst pain” item for 
deﬁ ning pain progression in CRPC patients using data collected as part of a multina-
tional phase III clinical trial. METHODS: Patients with a BPI-SF worst pain score ≥5 
were compared with patients with a score <5 in terms of Functional Assessment of 
Cancer Therapy—Prostate (FACT-P) subscales and total score and EQ-5D item scores. 
Exploratory analyses were also conducted to investigate any potential differences 
within designated regional subgroups of patients. All analyses were performed using 
treatment-blinded data collected at the ﬁ rst post-baseline trial visit including the above 
assessments (Week 12). RESULTS: A total of 464 patients completed the BPI-SF at 
W12 (<5 n = 411, ≥5 n = 53). Mean FACT-P total scores for patients with a BPI-SF 
worst pain score ≥5 were 24.5 points lower than for patients with a score <5 (91.1 
vs. 115.6, P < 0.0001), indicating poorer well-being. Patients with BPI-SF worst pain 
scores ≥5 consistently had lower scores for all FACT-P subscales (P < 0.0001) except 
for social well-being. The magnitude of these differences, for all scales, was consider-
ably greater than reported thresholds for meaningful difference. Results for EQ-5D 
item scores were in a similar direction with signiﬁ cantly greater impairment reported 
in patients with a BPI-SF worst pain score ≥5 compared with patients with a score <5 
(P < 0.0001). Exploratory analyses also revealed similar results across all regional 
subgroups of patients. CONCLUSIONS: Patient scores ≥5 on the BPI-SF “worst pain” 
item are associated with signiﬁ cant and meaningful impairments in CRPC patients, 
thus supporting the adequacy of this cutpoint as an appropriate deﬁ nition of pain 
progression in this population.
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OBJECTIVES: The standard lexicon for reporting adverse events in National Cancer 
Institute (NCI) sponsored clinical trials is the Common Terminology Criteria for 
Adverse Events (CTCAE), which consists of 790 individual items. Currently, all 
adverse events are reported by clinicians. However, multiple studies have found that 
clinicians tend to underreport symptom severity and onset compared with patient 
self-reports. In 2008, the NCI contracted a multi-institution consortium to develop 
patient versions of CTCAE items and an electronic platform for capturing symptoms 
from patients and reporting data to health care providers and researchers. METHODS: 
A committee including clinical investigators, methodologists, patients, and representa-
tives of NCI and FDA systematically identiﬁ ed CTCAE items with a subjective com-
ponent amenable to patient reporting. Systematic review and analyses of publications 
and existing symptom survey data sets and questionnaires were conducted to deter-
mine optimal formats for questions, response options, and terms for new PRO-CTCAE 
items. RESULTS: 81 symptoms were identiﬁ ed in the CTCAE to be amenable to 
patient reporting. The format and content of these items were found to be inappropri-
